GKT136901
CAS No. : 955272-06-7
| Size | Price | Stock |
|---|---|---|
| 5mg | $50 | In-stock |
| 10mg | $75 | In-stock |
| 25mg | $140 | In-stock |
| 50mg | $200 | In-stock |
| 100mg | $280 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-101499 |
| M.Wt: | 366.80 |
| Formula: | C19H15ClN4O2 |
| Purity: | >98 % |
| Solubility: | DMSO : 33.33 mg/mL (ultrasonic);H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) |
GKT136901 is a potent, selective and orally active inhibitor of NADPH oxidase (NOX1/4), with Kis of 160 and 165 nM, respectively. GKT136901 is also a selective and direct scavenger of peroxynitrite. GKT136901 can be used for the research of diabetic nephropathy, stroke, and neurodegeneration. GKT136901 also has anti-inflammatory activity[1][2][3].
IC50 & Target: Ki: 160 (NOX1), 165 (NOX4)[1]
In Vitro: GKT136901 (10 μM; 30 min) significantly attenuates high-D-glucose-induced increase in O2?? production and in H2O2 generation in MPT cells[4].
GKT136901 (10 μM; 30 min) abolishes the effect of high D-glucose on p38MAP kinase activation in MPT cells[4].
GKT136901 (10 μM; 2 h) attenuates methamphetamine (METH)-induced oxidative stress in HBMECs[5].
GKT136901 (10 μM; 2 h) protects HBMECs against METH-induced blood-brain barrier (BBB) dysfunction[5].
In Vivo: GKT136901 (30-90 mg/kg; daily p.o. for 16 weeks) has renoprotective effects in a mouse model of Type 2 diabetes[6].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- GKT136901
- Cat. No.:
- HY-101499
- Quantity:
Your information is safe with us.